Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

As regards the prognostic significance of the JAK2 haplotype GGCC_46/1 in AML cases, it was demonstrated that cases with a normal karyotype bearing the haplotype GGCC_46/1 showed a trend towards myelomonocytic proliferation and shorter disease-free survival and overall survival compared to GGCC_46/1 non carriers; on the other hand, the haplotype GGCC_46/1 had no impact on prognosis in the subgroup of AML with an abnormal karyotype [ 13 , 25 ].
Data from the primary prevention ICD patients with ischaemic heart disease enrolled in the Danish ICD registry also showed a trend towards higher mortality in men. 23 In patients with non-ischaemic cardiomyopathy, however, there was no difference in mortality. 16 In contrast to our results, the French DAI-PP registry only showed a lower mortality in women receiving a CRT-D (HR 0.68; P = 0.034) but no significant lower mortality of women in the overall primary prevention ICD cohort (HR 0.87; P = 0.32). 17 This difference to our findings can in part be explained by the fact that 61% of women in the French study but only 51% in our study received a CRT-D.
Vision-related quality of life showed a trend toward improvement in the DHA supplementation group at 45 and 90 days as compared with baseline, and a trend toward worsening in the control group (between-group differences P =0.037) ( Figure 5 ).
Subgroup analyses of ACR response rate, EULAR response, and proportion of patients with low disease activity and remission (according to the DAS28, SDAI, and CDAI) showed a trend toward decreased efficacy in antidrug antibody–positive patients (n = 84) compared with antidrug antibody–negative patients (n = 423) in all treatment groups (see Supplementary Table 1 , http://onlinelibrary.wiley.com/doi/10.1002/art.40444/abstract ).
The EORTC 26981/22981-NCIC CE3 study excluded patients over 70 [ 1 , 2 ], and although a subgroup analysis showed a trend toward benefit in patients over 60 years old, the degree of benefit diminished with increasing age [ 19 ].
Contemporary management of high-grade gliomas.
CNS Oncol · 2018 · PMC6001673
Looking at longer term effects, all methods showed a trend with the treatment effect becoming more negative through time, with truncated IPW estimating the largest difference in ppFEV 1 between those taking and not taking treatment of −8.81% (95% CI, −10.50 to −7.12, P < .001) and HA‐MSM the smallest effect of −1.52% (95% CI, −3.30 to 0.27, P = .097).